Cytomegalovirus Reactivation after Bendamustine-Based Chemotherapy: A Case Report

Author Department

Infectious Diseases; Pathology; Hematology/Oncology; Medicine

Document Type

Article, Peer-reviewed

Publication Date

9-2021

Abstract

Cytomegalovirus (CMV) is a DNA hepadnavirus, commonly implicated in reactivation disease after immunosuppression, especially in solid-organ and stem cell transplant patients. Bendamustine is an alkylating chemotherapeutic agent introduced into the management of hematological malignancies within the last decade. Few reports have raised potential concern for CMV reactivation disease after bendamustine therapy involving, but not limited to, the gastrointestinal tract, lungs, retina, and viremia. Cytomegalovirus reactivation in such instances should be added to the differential diagnoses for febrile nonneutropenic immunocompromised patients. Here, we report a case of an elderly gentleman recently diagnosed with mantle cell lymphoma who was started on chemotherapy with rituximab, bendamustine, and dexamethasone and developed CMV colitis and viremia after just 2 cycles of chemotherapy. © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Author keywords

bendamustine; cytomegalovirus; cytomegalovirus disease; cytomegalovirus reactivation

Link to Full Text

Share

COinS